Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Major investors are betting that a Durham company has a potential cure for hepatitis B. A biotechnology company in Durham has closed a $175 million funding round to support its efforts to develop ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.